The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC).
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kowa; Lilly Japan; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Bayer; Bayer Yakuhin; Bristol-Myers Squibb; Lilly Japan; NanoCarrier
Research Funding - AstraZeneca; Baxter; Bayer Yakuhin; Boehringer Ingelheim; Eisai; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
 
Kenji Ikeda
Honoraria - Dainippon Sumitomo Pharma; Eisai
 
Masatoshi Kudo
Honoraria - Bayer; EA Pharma; Eisai; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai
Research Funding - Bayer; Chugai Pharma; Daiichi Sankyo; MSD; Otsuka; Sumitomo Dainippon; Taiho Pharmaceutical
 
Yukio Osaki
Honoraria - Eisai
 
Takuji Okusaka
Honoraria - Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Dainippon Sumitomo Pharma; Lilly; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Novartis; OncoTherapy Science; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan; Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; Kowa; Lilly; Merck Serono; Nippon Boehringer Ingelheim; Novartis; OncoTherapy Science; Otsuka; Pfizer; Sceti Medical Labo; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Toshiyuki Tamai
Employment - Eisai
Stock and Other Ownership Interests - Eisai
 
Takuya Suzuki
Employment - Eisai
 
Takashi Hisai
Employment - Eisai
Stock and Other Ownership Interests - Eisai
 
Hideaki Miyagishi
Employment - Eisai
 
Kiwamu Okita
No Relationships to Disclose
 
Hiromitsu Kumada
Honoraria - Abbvie; Ajinomoto; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline K.K.; Janssen; Kowa; Merck Sharp & Dohme; Mitsubishi Tanabe Pharma; Otsuka; Sumitomo Dainippon; Toray Industries; Toray Industries